Long COVID ‐19 gastrointestinal related disorders and traditional Chinese medicine: A network target‐based approach
Phytotherapy Research · 2024
DOI: 10.1002/ptr.8163 ↗At a glance
Übersichtsarbeit in Phytotherapy Research, 2024. Written by Laura Beatrice Mattioli and 6 co-authors. Institution: Department of Pharmacy and Biotechnology, Food Chemistry and Nutraceutical Lab, Alma Mater Studiorum-University of Bologna, Bologna, Italy. Major MEDLINE topics: Medicine, Chinese Traditional, COVID-19, Gastrointestinal Diseases, Drugs, Chinese Herbal. Cited 11 times so far (Crossref); 204 references.
Abstract (original language)
The significant number of individuals impacted by the pandemic makes prolonged symptoms after COVID‐19 a matter of considerable concern. These are numerous and affect multiple organ systems. According to the World Health Organization (WHO), prolonged gastrointestinal issues are a crucial part of post‐COVID‐19 syndrome. The resulting disruption of homeostasis underscores the need for a therapeutic approach based on compounds that can simultaneously affect more than one target/node. The present review aimed to check for nutraceuticals possessing multiple molecular mechanisms helpful in relieving Long COVID‐19‐specific gastrointestinal symptoms. Specific plants used in Keywords Chinese Medicine (TCM) expected to be included in the WHO Global Medical Compendium were selected based on the following criteria: (1) they are widely used in the Western world as natural remedies and complementary medicine adjuvants; (2) their import and trade are regulated by specific laws that ensure quality and safety (3) have the potential to be beneficial in alleviating intestinal issues associated with Long COVID‐19. Searches were performed in PubMed, Elsevier, Google Scholar, Scopus, Science Direct, and ResearchGate up to 2023. Cinnamomum cassia , Glycyrrhiza uralensis , Magnolia officinalis , Poria cocos , Salvia miltiorrhiza , Scutellaria baicalensis , and Zingiber officinalis were identified as the most promising for their potential impact on inflammation and oxidative stress. Based on the molecular mechanisms of the phytocomplexes and isolated compounds of the considered plants, their clinical use may lead to benefits in gastrointestinal diseases associated with Long COVID‐19, thanks to a multiorgan and multitarget approach.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy and Biotechnology, Food Chemistry and Nutraceutical Lab, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
- Department of Life Sciences, University of Siena, Siena, Italy.
- Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, Bologna, Italy.
- Internal Medicine Unit, Azienda USL, Budrio Hospital, Bologna, Italy.
- Unit of Gastroenterology & Digestive Endoscopy, Sandro Pertini Hospital, Rome, Italy.
- Department of Biomolecular Sciences, Università degli Studi di Urbino "Carlo Bo", Urbino, Italy.
ORCID profiles: Laura Beatrice Mattioli, Roberta Budriesi
Cite
APA
Mattioli, L. B., Frosini, M., Corazza, I., Fiorino, S., Zippi, M., Micucci, M., & Budriesi, R. (2024). Long COVID ‐19 gastrointestinal related disorders and traditional Chinese medicine: A network target‐based approach. Phytotherapy Research. https://doi.org/10.1002/ptr.8163
Vancouver
Mattioli LB, Frosini M, Corazza I, Fiorino S, Zippi M, Micucci M, et al. Long COVID ‐19 gastrointestinal related disorders and traditional Chinese medicine: A network target‐based approach. Phytotherapy Research. 2024. doi:10.1002/ptr.8163
BibTeX
@article{Mattioli2024,
author = {Mattioli, Laura Beatrice and Frosini, Maria and Corazza, Ivan and Fiorino, Sirio and Zippi, Maddalena and Micucci, Matteo and Budriesi, Roberta},
title = {Long COVID ‐19 gastrointestinal related disorders and traditional Chinese medicine: A network target‐based approach},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.8163}
}
EUVIMED